Single dose of HPV vaccine can protect from cervical cancer
In a recent study, researchers indicated that a single dose of the human papillomavirus (HPV) vaccine is as effective as multiple doses for preventing preinvasive cervical disease, which can later develop into cervical cancer.
HPV is the most common sexually transmitted infection in the United States, and persistent infection with certain types of the virus can cause cervical cancer.
To prevent infection, the Centers for Disease Control and Prevention recommended that adolescents both boys and girls under the age of 15 years receive a two-dose schedule of the HPV vaccine.
To determine the effectiveness of other dose schedules, Ana M. Rodriguez, MD, MPH, of The University of Texas Medical Branch at Galveston, and her colleagues examined information on females aged 9 to 26 years who were unvaccinated or who received one or more HPV vaccine doses between January 2006 and June 2015.
The findings of the research are published early online in 'CANCER', a peer-reviewed journal of the American Cancer Society (ACS).
The analysis included 133,082 females (66,541 vaccinated and 66,541 unvaccinated). For females ages, 15 to 19 years, those who received one, two, or three doses of the HPV vaccine had lower rates of preinvasive cervical disease than adolescents who were unvaccinated. Within five years, 2.65 per cent of unvaccinated teens aged 15 to 19 years developed the preinvasive cervical disease, compared with 1.62 per cent, 1.99 per cent, and 1.86 per cent in the one-, two- and three-dose groups, respectively.
The risk of preinvasive cervical disease was 36 per cent, 28 per cent, and 34 per cent lower for adolescents who received one, two, and three doses, respectively, compared with adolescents who were unvaccinated.
For the youngest (less than 15 years old) and oldest age groups (20 years and older), the investigators did not find significant differences among the vaccinated groups in terms of risk for preinvasive cervical disease.